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Congenital hyperinsulinism causes profound hypoglycemia, which may persist or resolve spontaneously. Among
13 children with congenital hyperinsulinism, elevated incretin hormone concentrations were detected in 2with atyp-
ical, persistent disease.We suggest that incretin biomarkersmay identify these patients, and that elevated hormone
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ongenital hyperinsulinism (CHI), characterized by
inappropriate release of insulin from pancreatic b cells,
is associated with brain injury due to hypoglycemia.1-3
The severity of hyperinsulinism varies and may be transient
or persistent. More than 70% of all patients with CHI currently
have no identified genetic basis.4-6 Themost common causes of
persistent CHI aremutations in theABCC8 andKCNJ11 genes,
which cause focal (CHI-F) or diffuse (CHI-D) histological var-
iants ofCHI.1,2 A recently described histopathological variant of
CHI, termed atypical CHI (CHI-A), accounts for 10% of pa-
tients undergoing pancreatectomy for treatment of CHI.7 Diag-
nosing CHI-A is difficult because no associatedmutations have
been reported, affected patients are variably responsive tomed-
ications, and imaging with fluorine-18-labeled L-dihydroxy-
phenylalanine positron emission tomography and computed
tomography, which differentiates between CHI-F and CHI-D,
is unable to identify CHI-A.7
The incretin hormones glucose-dependent insulinotropic
peptide (GIP) and glucagon-like peptide 1 (GLP-1) are
secreted from enteroendocrine cells and exert a substantial reg-
ulatory influence on insulin secretion.8 The aim of the present
study was to compare fasting and postprandial plasma GLP-1
and GIP concentrations among patients with persistent forms
of CHI (CHI-F, CHI-D, and CHI-A) and those patients with
transient disease. Our results suggest a positive association be-
tween an elevated GLP-1 (7-36):GIP andCHI-A, which should
be investigated as a potential diagnostic biomarker for CHI-A.
Methods
Thirteen patients with CHI were recruited with local Ethical
Board approval and parental consent at a UK NationalCHI Congenital hyperinsulinism
CHI-A Atypical congenital hyperinsulinism
CHI-D Diffuse congenital hyperinsulinism
CHI-F Focal congenital hyperinsulinism
GIP Glucose-dependent insulinotropic peptide
GLP-1 Glucagon-like peptide 1Referral Centre for CHI. The Table summarizes the
patients’ clinical profiles, with the classification of CHI
based on established diagnostic criteria.1,2,4,9 Sequence
analysis of the exons and intron/exon boundaries of the
ABCC8 and KCNJ11 genes was performed on all patients
using genomic DNA extracted from peripheral blood
leukocytes. ABCC8 analysis included screening for the
recently reported deep intronic cryptic splicing mutation.10
No further testing was performed in the patients with
transient CHI. In the patients with atypical disease, Sanger
sequencing of the exons and intron/exon boundaries of the
HADH, GCK, and HNF4A genes was performed. HNF4A
analysis included the coding exons 1d-10 and the P2
pancreatic promoter, and HADH analysis included
screening for the deep intronic splicing mutation.10
For analysis of plasma peptides, patients fasted for 4 hours
before blood sample collection and more bloods samples
were collected 20 minutes (30 minutes for patients subjected
to an oral glucose tolerance test) after the start of feeding.
Formula feeds (Table), obtained from Nutricia
(Trowbridge, United Kingdom), were given at a rate of
20 mL/kg body weight. Two patients (2 and 13) were
subjected to standard oral glucose tolerance test.
All samples were centrifuged at 1300 g for 10 minutes at
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Table. Clinical characteristics of the CHI patient cohort
Patient
Classification
of CHI
Age at
diagnosis
Age at
sample
collection,
mo
Birth
weight,
kg
Gestation,
wk
Genetic
cause
Medical
treatment
Surgical
treatment Outcome Feed
1 Transient 6 d 1 2.08 38 Unknown Diazoxide No Normoglycemic Breast milk
2 Transient 1 y 190 3.45 40 + 2 Unknown Diazoxide No Normoglycemic OGTT
3 Transient 4 d 16 2.86 40 Unknown Diazoxide No Normoglycemic Nutrini Peptisorb
4 Transient 2 d 24 3.5 40 Unknown Diazoxide No Normoglycemic Polycal
5 Transient 1 d 1 2.49 40 Unknown Diazoxide No Normoglycemic Cow & Gate/
Polycal
6 Diffuse 2 d 27 4.4 40 ABCC8
Comp hetero
Octreotide No Continuous
therapy
Nutrini Peptisorb
7 Diffuse 3 d 26 3.25 40 ABCC8
Maternal
Diazoxide No Continuous
therapy
Nutrini Peptisorb
8 Diffuse 4 d 51 3.4 42 KCNJ11
Paternal
Diazoxide/
octreotide
No Continuous
therapy
Nutrini Peptisorb
9 Diffuse 6 d 33 4.73 40 ABCC8
Homozygous
Diazoxide/
octreotide
Near-total
pancreatectomy
Cured Whole milk
10 Focal 3 mo 49 3.62 40 ABCC8
Paternal
Diazoxide Subtotal
pancreatectomy
Cured Whole milk
11 Focal 7 d 48 4.9 38 + 5 ABCC8
Paternal
Diazoxide/
octreotide
Subtotal
pancreatectomy
Cured Infantrini
12 Atypical 2 y, 7 mo 36 2.72 34 Unknown Diazoxide/
octreotide
Near-total
pancreatectomy
Cured Nutrini Peptisorb
13 Atypical 21 mo 37 3.4 40 Unknown Diazoxide No Continuous
therapy
OGTT
Comp hetero, compound heterozygous; OGTT, oral glucose tolerance test.
All patients were treated for hypoglycemia and classified as transient, diffuse, focal, or atypical based on clinical characteristics, genotyping, fluorine-18 labeled L-dihydroxyphenylalanine positron
emission tomography and computed tomography diagnosis or pancreatic histology after surgery. Four patients with persistent disease (patients 9-12) underwent surgery to alleviate hyperinsulinism;
samples for this study were obtained after recovery from surgery. Patients 1-5 and 8-11 were sampled in the absence of drug treatment. For transient patients, disease resolution occurred by follow-
up visits at age 8 months (patient 1), 5 years (patient 2), 9 months (patient 3), 15 months (patient 4), and 5 months (patient 5). Four patients with persistent disease are currently receiving medical
interventions (patients 6, 7, 8, and 13) and were sampled during ongoing treatment.
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concentrations were assessed in triplicate by enzyme-linked
immunosorbent assay (ALPCO, Salem, New Hampshire
and EMD Millipore, Billerica, Massachusetts, respectively).
Incretin hormone concentrations and ratios were analyzed
for differences between all patient groups. Statistical signif-
icance was determined by 1-way ANOVA and the Tukey
post hoc test where appropriate, with a P value <.05 consid-
ered significant. All data are presented as mean  SEM.
Results
All patients were screened for mutations in ABCC8/KCNJ11
(Table). Two patients (12 and 13) had late-onset
presentation of persistent CHI, with no characteristic
triggers for hypoglycemic events, and both were genotype-
negative for defects in ABCC8, KCNJ11, HADH, GCK, and
HNF4A. After decline and eventual failure of responses to
medical therapy, patient 12 required a 95%
pancreatectomy. Examination of the resected pancreas
revealed a heterogeneous pattern of pancreatic
histopathology and abnormal expression of hexokinase 1,
suggestive of CHI-A based on published criteria.7,11
In all patients, postprandial incretin concentrations
increased above basal levels, with no differences between the
patients with CHI-F and those with CHI-D when analyzed
separately (Figure). The average basal GLP-1 (7-36) and GIP
concentrations were not significantly different across the
patient groups (transient CHI vs persistent CHI-F/CHI-D192and CHI-A). On average, postprandial GLP-1 (7-36)
concentrations increased to 3.9  0.9 pmol/L in the patients
with transient CHI (n = 4) and to 4.3  1.0 pmol/L in those
with CHI-F/CHI-D (n = 6), and was markedly higher in the
patients with CHI-A, measured at 82.2 pmol/L in patient 12
and 16.5 pmol/L in patient 13 (P < .05; Figure, A). These 2
patients with atypical disease also exhibited greater fold
changes in postprandial GIP concentrations, increasing by
14-fold, compared with 8-fold in patients with transient CHI
and 7-fold in those with CHI-F/CHI-D (Figure, B).
The postprandial GLP-1 (7-36):GIP was similar in patients
with transient CHI and those with CHI-F/CHI-D (0.1 0.03
[n = 4, patients 1-4] vs 0.13 0.03 [n = 6, patients 6-11]), but
was markedly elevated in patients with CHI-A (0.52  0.06,
P < .001; n = 2, patients 12 and 13) (Figure, C).
Discussion
Incretin hormones have potent regulatory effects on hor-
mone secretion, and inappropriately increased GLP-1 or
GIP secretion after gastric surgery has been linked to hyper-
insulinemic hypoglycemia.12,13 In the present study, 2 pa-
tients with CHI-A had strikingly higher postprandial
GLP-1 (7-36):GIP compared with patients with CHI-F,
CHI-D, or transient CHI (Figure).
In patients with CHI-A, the genetic basis of disease is un-
known and may vary, although heterogeneous expression of
hexokinase 1 in b cells is associated with inappropriate insu-
lin release in atypical patients requiring pancreatectomy.11Shi et al
Figure. A andB,Basal and postprandial (“stimulated”) concentrations of GLP-1 (7-36) andGIP in patients with CHI.C,GLP-1 (7-
36):GIP in the 3 patient groups. The integrated incretin ratio values showed no differences in the transient and CHI-F/CHI-D
patient groups, but was significantly larger in patients with CHI-A (P < .001).
January 2015 CLINICAL AND LABORATORY OBSERVATIONSWe found a similar profile of hexokinase 1 expression in b
cells in the tissue of patient 12, but could not evaluate this
in patient 13, who was stable on medical therapy. Interest-
ingly, studies on rat insulinoma cell lines have demonstrated
up-regulation of hexokinase 1 gene expression in response to
GLP-1 and GIP in vitro, suggesting a possible link between
incretin pathology and CHI-A.14,15
Despite variable incretin secretion stimuli in the pa-
tients in this study and ongoing medical treatment that
may have minimized observed differences, both patients
with CHI-A had a markedly elevated postprandial GLP-1
(7-36):GIP compared with the other patient groups. Our
preliminary findings suggest an alternative cause of hyper-
insulinemic hypoglycemia independent of KATP channel–
driven mechanisms that may affect b cells directly or
may increase insulin secretion via enhanced incretin ac-
tion. We speculate that both of our patients with CHI-A
possibly would have benefited from the GLP-1 receptor
antagonist–based therapy described by Calabria et al,16
which in 1 patient might have obviated the need for
near-total pancreatectomy.
In summary, CHI-A currently represents a subgroup of pa-
tients with persistent and medically unresponsive hypoglyce-
mia that cannot be detected by imaging techniques and for
which there is no genetic or endocrine biomarker. Based on
our observations, we suggest that investigation of plasma in-
cretin profiles in patients with CHImay identify this group of
patients to be followed up in multicenter studies. n
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